Use of insulin pumps in India: suggested guidelines based on experience and cultural differences.
All type 1 diabetes mellitus (T1DM) subjects and the majority of type 2 diabetes mellitus (T2DM) subjects at one time or another require insulin to sustain life. Syringes and pens are presently the most popular insulin delivery devices. Though in use for more than 3 decades, insulin pumps are now being more commonly used because of their unique ability to continuously infuse insulin, closely mimicking that of physiological secretion from a normal pancreas. Unlike insulin shots with syringes, pump infusion sites need to be changed less frequently. Scientific evidence from published studies have proven added benefit of insulin pumps in improving quality of life, normalizing sugars in recalcitrant diabetes, improving sexual function, and relieving the intractable pain of neuropathy. In the western world, pumps are commonly used with T1DM subjects, whereas in India 80% of pumpers are T2DM subjects. The success of insulin pump therapy depends on selection of the right candidate, extensive education, motivation, and implementing the sophisticated programs with skill. However, all affordable patients are not ideal candidates for pump therapy because for successful continuation of pump therapy other inclusion criteria should also be fulfilled. Among the other indications discussed are a high level of insulin resistance, brittle diabetes, chronic kidney disease on renal replacement therapy, and continuous glucose monitoring pattern strongly suggesting need for a variable basal insulin infusion rate. In International Diabetes Foundation data released in 2009, estimated diabetes prevalence for 2010 is 285 million, representing 6.4% of the world's adult population, with a prediction that by 2030 the number of people with diabetes will have increased to 438 million. Considering this massive growth in T2DM and its propensity after 10–15 years to lead to an insulin-deficient state, available evidence from studies is a compelling indication not to deny the benefits of continuous subcutaneous insulin infusion in selected T2DM subjects. This article aims at suggesting guidelines based on clinical experience and cultural diversity for India and developing countries.
Kesavadev
Jothydev
J
Jothydev's Diabetes and Research Center, Trivandrum, Kerala, India. jothydev@vsnl.com
Das
Ashok Kumar
AK
Unnikrishnan
Ranjit
R
Joshi
Shashank R
SR
Ramachandran
Ambady
A
Shamsudeen
Jisha
J
Krishnan
Gopika
G
Jothydev
Sunitha
S
Mohan
Viswanathan
V
D017028:Caregivers / Q000523:psychology; D003020:Clothing; D000075202:Contraindications; D003431:Cross-Cultural Comparison; D003906:Developing Countries; D048909:Diabetes Complications / Q000517:prevention & control; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000208:ethnology*; D006801:Humans; D007194:India; D007332:Insulin Infusion Systems / Q000191:economics / Q000523:psychology; D018579:Patient Selection; D017410:Practice Guidelines as Topic; D012648:Self Care / Q000523:psychology
N Engl J Med. 1993 Sep 30;329(14):977-86
8366922
Clin Ther. 2007;29 Suppl D:S135-44
18191065
Lancet. 1998 Sep 12;352(9131):837-53
9742976
Diabetes Care. 2008 Feb;31 Suppl 2:S140-5
18227475
Diabetes Care. 2001 Jul;24(7):1299
11423521
Diabetes Care. 2008 Feb;31 Suppl 2:S150-4
18227477
Diabetes Care. 2010 Jan;33 Suppl 1:S4-10
20042774
Diabetes Technol Ther. 2009 Nov;11(11):733-7
19905890
J Assoc Physicians India. 1983 Nov;31(11):715-7
6671951
Diabetes Technol Ther. 2009 Aug;11(8):517-21
19698065
Diabetes Care. 2010 Jan;33(1):67-72
19808919
N Engl J Med. 2008 Jun 12;358(24):2560-72
18539916
Diabetes Care. 2009 Jan;32 Suppl 1:S13-61
19118286
J R Soc Med. 2001 Nov;94(11):578-80
11691895